Sequenom Announces Contract with Anthem BlueCross

Agreement covers Noninvasive Prenatal Tests in California

Mar 02, 2016, 16:39 ET from Sequenom, Inc.

SAN DIEGO, March 2, 2016 /PRNewswire/ -- Sequenom, Inc., (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced the completion of an agreement with Anthem BlueCross.  The agreement provides in-network coverage for Anthem's California customers for Sequenom Laboratories' noninvasive prenatal tests in both high and average risk pregnancies, beginning March 1, 2016. 

"We are excited to be contracted with Anthem BlueCross," said Dr. Dirk van den Boom, PhD, President and CEO of Sequenom. "Our contract with Anthem is another important step in our strategy to be an in-network provider and to bring the benefits of noninvasive prenatal testing to as many patients as possible, including women with average-risk pregnancies." 

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a pioneering genetic testing company dedicated to women's health through the development of innovative products and services.  The Company serves patients and physicians by providing early patient management information.  For more information, visit

About Sequenom Laboratories

Sequenom Laboratories, a CAP-accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests, with a focus principally on prenatal care. Branded under the names HerediT®, HerediT® UNIVERSAL, MaterniT® GENOME, MaterniT21® PLUS, NextView®, SensiGene® and VisibiliT, these molecular genetic laboratory-developed tests provide early patient management information for obstetricians, geneticists, and maternal fetal medicine specialists. Sequenom Laboratories is changing the landscape in genetic diagnostics using proprietary cutting edge technologies. Visit and follow @SequenomLabs.

SEQUENOM®, HerediT®, MaterniT®, NextView®, SensiGene®, VisibiliT and Sequenom Laboratories are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the development of innovative products and services and the ability to bring the benefits of noninvasive prenatal testing to as many patients as possible.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in the Company's filings with the Securities and Exchange Commission, including without limitation the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Logo -


SOURCE Sequenom, Inc.